EASL 2017: Albumin Reduces Complications of Decompensated Cirrhosis and Improves Survival
- Details
- Category: Decompensation & ESLD
- Published on Wednesday, 03 May 2017 00:00
- Written by Liz Highleyman
Long-term administration of human album was associated with fewer serious complications, less hospitalization, better quality of life, and longer survival for people with decompensated liver cirrhosis, according to a report at the EASL International Liver Congress last month in Amsterdam.
EASL 2017: Besifovir and Tenofovir Exalidex Look Promising for Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Published on Wednesday, 03 May 2017 00:00
- Written by Liz Highleyman
A pair of investigational nucleotide analog antivirals were shown to be active against hepatitis B virus (HBV) with minimal potential for kidney and bone toxicity, researchers reported at the EASL International Liver Congress last month in Amsterdam. Besifovir is in Phase 3 clinical trials, while tenofovir exalidex is in early development.
EASL 2017: Generic Hepatitis C Drugs Continue to Produce High Cure Rates
- Details
- Category: Approved HCV Drugs
- Published on Monday, 01 May 2017 00:00
- Written by Keith Alcorn
Treatment with generic versions of direct-acting antiviral drugs (DAAs) for hepatitis C continues to produce similar cure rates to those reported in clinical trials of brand-name drugs, James Freeman reported last month at the EASL International Liver Congress in Amsterdam.
EASL 2017: Triple Combination Cures Most Hepatitis C Patients with Prior DAA Failure
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 01 May 2017 00:00
- Written by Liz Highleyman
Almost all people with genotype 1 hepatitis C who were previously unsuccessfully treated with a course of interferon-free direct-acting antiviral therapy achieved sustained response when retreated with a 3-drug combination being developed by Merck, researchers reported at the EASL International Liver Congress last month in Amsterdam.
EASL 2017: Hepatitis C Treatment Allows 1 in 4 to Come Off Liver Transplant Waiting List
- Details
- Category: Liver Cancer/HCC
- Published on Monday, 01 May 2017 00:00
- Written by Keith Alcorn
Around a quarter of people with hepatitis C and decompensated cirrhosis came off liver transplant waiting lists in Europe after direct-acting antiviral (DAA) treatment, and very few had any subsequent liver-related problems during 15 months of follow-up, Luca Belli reported on behalf of the ELITA study investigators at the EASL International Liver Congress last month in Amsterdam.
More Articles...
- EASL 2017: WHO Releases Global Hepatitis Report
- EASL 2017: EASL Releases Updated Hepatitis B Guidelines at International Liver Congress
- EASL 2017: Switching to TAF for Hepatitis B Improves Kidney Function and Bone Loss
- EASL 2017: New AbbVie Hepatitis C Combination Cures 99% of People with Cirrhosis
- EASL 2017: Norfloxacin Reduces Risk of Death for People with Decompensated Cirrhosis
- EASL 2017: Children with Hepatitis C Respond Well to Sofosbuvir/Ledipasvir
- EASL 2017: AbbVie Combination Cures Most People with Genotype 3 Hepatitis C
- EASL 2017: Curing Hepatitis C Reduces Cardiovascular Risk
- EASL 2017: European HCV Treatment Access Survey Shows Big Variations in Eligibility
- EASL 2017: Direct-Acting Antivirals for Hepatitis C Not Linked to Higher Liver Cancer Risk
- EASL 2017: Nivolumab Increases Survival for People with Advanced Liver Cancer
- EASL 2017: International Liver Congress Starts This Week in Amsterdam
Web Design and Development by